Dexrazoxane Hydrochloride – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 83 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Dexrazoxane Hydrochloride - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Dexrazoxane Hydrochloride is the hydrochloride salt of a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Dexrazoxane Hydrochloride is the hydrochloride salt of a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition. Dexrazoxane is a...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Dexrazoxane Hydrochloride is the hydrochloride salt of a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.

Dexrazoxane is a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.

Dexrazoxane is a cytoprotective drug used to prevent and improve cardiomyopathy associated with doxorubicin treatment for metastatic breast cancer. An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit the formation of a toxic iron-anthracycline complex. [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.

Mechanism of Action

The mechanism by which dexrazoxane exerts its cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of EDTA that readily penetrates cell membranes. Results of laboratory studies suggest that dexrazoxane (a prodrug) is converted intracellularly to a ring-opened bidentate chelating agent that chelates to free iron and interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy. It should be noted that dexrazoxane may also be protected through its inhibitory effect on topoisomerase II.

or

The mechanism of action of dexrazoxane’s cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of ethylenediamine tetra-acetic acid (EDTA) that readily penetrates cell membranes. Laboratory studies suggest that dexrazoxane is converted intracellularly to a ring-opened chelating agent that interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy.

Dexrazoxane is a cardioprotective agent for use in conjunction with doxorubicin indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose. Patients receiving anthracycline-derivative antineoplastic agents may experience three types of cardiotoxicity: acute transient type; chronic, subacute type (related to cumulative dose and has a more indolent onset later on); and a late-onset type that manifests years after therapy, mainly in patients that have been exposed to the drug as a child. Although the exact mechanism of anthracycline-induced cardiotoxicity is not known, it has been shown to exert a variety of actions that may result in the development of cardiotoxicity. In animals, anthracyclines cause a selective inhibition of cardiac muscle gene expression for α-actin, troponin, myosin light-chain 2, and the M isoform of creatine kinase. This may lead to myofibrillar loss associated with anthracycline-induced cardiotoxicity. Anthracyclines may also cause myocyte damage via calcium overload, altered myocardial adrenergic function, the release of vasoactive amines, and proinflammatory cytokines. Furthermore, it has been suggested that the main cause of anthracycline-induced cardiotoxicity is associated with free-radical damage to DNA. The drugs intercalate DNA, chelate metal ions to produce drug-metal complexes, and generate superoxide radicals via oxidation-reduction reactions. Anthracyclines also contain a quinone structure that can undergo reduction via NADPH-dependent reactions to produce a semiquinone free radical that initiates a cascade of superoxide and hydroxide radical generation. Chelation of metal ions, particularly iron, by anthracyclines results in an anthracycline-metal complex that catalyzes the generation of reactive oxygen free radicals. This complex is a powerful oxidant that can initiate lipid peroxidation in the absence of oxygen free radicals. The toxicity induced by anthracyclines may be exacerbated in cardiac cells, as these cells do not possess sufficient amounts of certain enzymes (e.g., superoxide dismutase, catalase, glutathione peroxidase) involved in detoxifying free radicals and protecting the cells from subsequent damage.

Indications

  • For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.
  • Save is indicated for the treatment of anthracycline extravasation.
  • Dexrazoxane is indicated for reducing the incidence and severity of cardiomyopathy associated with the administration of doxorubicin in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/sq m of the body surface and who would benefit from continued therapy with doxorubicin.
  • Accidental extravasation of chemotherapy containing anthracycline often causes mutilating complications as a result of extensive tissue necrosis. Treatment, therefore, consists of extensive surgical debridement.
  • Reducing incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin.

FDA-approved indications:

  • Reduction of incidence and severity of cardiac dysfunction associated with anthracycline use.
  • Dexrazoxane can also be used to treat tissue damage caused by anthracyclines when they leak from the vein while being administered.

Non-FDA-approved indication:

  • Although a study is still underway as of this writing, dexrazoxane may act as a beneficial neuroprotectant to treat neurodegeneration in patients with Parkinson’s disease.

Use in Cancer

Dexrazoxane hydrochloride is approved to treat severe side effects caused by certain types of chemotherapy. It is used to treat the following:

  • Cardiac (heart) side effects caused by doxorubicin hydrochloride in women being treated for metastatic breast cancer. Dexrazoxane hydrochloride helps make the side effects happen less often and makes them less severe when they do occur. It is used only in women who have already received high doses of doxorubicin and continue to be treated with it. This use is approved for the Totect and Zinecard brands of dexrazoxane hydrochloride.
  • Extravasation caused by intravenous anthracyclines. Extravasation occurs when injected drugs leak out of the vein, into the surrounding tissue. This can cause redness, pain, and swelling, and may damage the tissue. This use is approved for the Totect brand of dexrazoxane hydrochloride.

Contraindications

  • decreased blood platelets
  • low levels of white blood cells
  • low levels of a type of white blood cell called neutrophils
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • chronic kidney disease stage 3B (moderate)
  • chronic kidney disease stage 4 (severe)
  • chronic kidney disease stage 5 (failure)
  • kidney disease with likely reduction in kidney function

Dosage

 Strengths: 250 mg; 500 mg

Cardiomyopathy Prophylaxis

The dosage ratio of dexrazoxane to doxorubicin is 10:1 (e.g. 500 mg/m2 dexrazoxane to 50 mg/m2 doxorubicin)

  • Administer via IV infusion over 15 minutes.
  • DO NOT administer via IV push.
  • Administer doxorubicin within 30 minutes of completion of dexrazoxane infusion; do not administer doxorubicin before dexrazoxane.
  • Do not use it with the initiation of doxorubicin therapy.

Extravasation

Recommended doses:

  • Day one: 1000 mg/m2 IV over 1 to 2 hours
  • Day two: 1000 mg/m2 IV over 1 to 2 hours
  • Day three: 500 mg/m2 IV over 1 to 2 hours

Maximum doses:

  • Day one: 2000 mg
  • Day two: 2000 mg
  • Day three: 1000 mg
  • The product must be diluted with 50 mL of 0.167 M sodium lactate injection solution prior to administration.
  • Initiate the first infusion as soon as possible and within the first 6 hours of extravasation.
  • Start day 2 and 3 treatments at the same hour as the first day (give or take 3 hours).
  • Remove cooling features such as ice packs (if used) at least 15 minutes before administration to allow sufficient blood flow to the extravasation area.

Side Effects

The Most Common

  • pain or swelling in the place where the medication was injected
  • nausea
  • vomiting
  • diarrhea
  • constipation
  • stomach pain
  • loss of appetite
  • dizziness
  • pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache
  • excessive tiredness
  • difficulty falling asleep or staying asleep
  • depression
  • swelling of the arms, hands, feet, ankles, or lower legs
  • sore throat, fever, chills, cough, and other signs of infection
  • unusual bruising or bleeding
  • pale skin
  • weakness
  • shortness of breath
  • rash
  • itching
  • hives
  • difficulty breathing or swallowing
  • swelling of the eyes, face, mouth, lips, tongue, or throat
  • dizziness
  • fainting

More common

  • Blurred or double vision
  • diarrhea
  • difficulty having a bowel movement
  • difficulty in swallowing
  • difficulty in walking
  • discouragement
  • dizziness
  • drooping eyelids
  • fainting
  • feeling sad or empty
  • hair loss
  • pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache
  • heartburn
  • irritability
  • jaw pain
  • lack or loss of appetite
  • lightheadedness
  • loss of interest or pleasure
  • muscle pain, spasms, cramps, or stiffness
  • nausea
  • numbness or tingling in the fingers and toes
  • pain in the fingers and toes
  • pain in the testicles
  • pain or burning in the throat
  • pain or redness at the site of injection
  • pale skin at the site of injection
  • rapid, shallow breathing
  • stomach pain
  • swelling or inflammation of the mouth
  • thinning of the hair
  • trouble concentrating
  • trouble sleeping
  • vomiting
  • weight loss

Rare

  • Bluish color
  • changes in skin color
  • chest pain or tightness
  • chills
  • cold hands and feet
  • cough
  • fever
  • hoarseness
  • lower back or side pain
  • pain, redness, or swelling in the arm or leg
  • painful or difficult urination
  • pale skin
  • sneezing
  • sore throat
  • swelling of the hands, ankles, feet, or lower legs
  • tenderness
  • trouble breathing
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • Black, tarry stools
  • chest discomfort
  • fast, irregular, or pounding heartbeat
  • pain at the injection site
  • ulcers, sores, or white spots in the mouth

Drug Interactions

Pregnancy and Lactation

FDA Pregnancy Risk Category: C 

Pregnancy

The manufacturer makes no recommendation regarding use during pregnancy. This drug can cause fetal harm; if this drug is used during pregnancy, or the patient becomes pregnant, apprise them of the potential hazard to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 3 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose.

Lactation

No information is available on the use of dexrazoxane during breastfeeding. The manufacturer recommends that women not breastfeed during treatment and for 2 weeks following the final dose of dexrazoxane. However, because dexrazoxane is used with doxorubicin, the abstinence period might be longer, depending on the doxorubicin dose.

How should this medicine be used?

Dexrazoxane injection comes as a powder to be mixed with liquid and injected into a vein by a doctor or nurse in a hospital. When dexrazoxane injection is used to prevent heart damage caused by doxorubicin, it is given over 15 minutes just before each dose of doxorubicin. When dexrazoxane injection is used to prevent tissue damage after an anthracycline medication has leaked out of a vein, it is given over 1 to 2 hours once a day for 3 days. The first dose is given as soon as possible within the first 6 hours after the leak occurs, and the second and third doses are given about 24 and 48 hours after the first dose.

What special precautions should I follow?

Before receiving dexrazoxane injection,

  • tell your doctor and pharmacist if you are allergic to dexrazoxane, any other medications, or any ingredients in dexrazoxane injection. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention dimethylsulfoxide (DMSO) topical products.
  • tell your doctor if you have or have ever had heart, kidney, or liver disease.
  • tell your doctor if you are pregnant, plan to become pregnant, or plan to father a child. You should not become pregnant while you are receiving dexrazoxane injections. If you are receiving a dexrazoxane injection (Zinecard), you should use birth control during your treatment. If you are receiving dexrazoxane injection (Totect), you should use birth control during your treatment and for at least 6 months after your final dose. If you are male, you and your female partner should use birth control during your treatment and for 3 months after you stop receiving dexrazoxane injections (Protect). Talk to your doctor about birth control methods that will work for you. If you or your partner become pregnant while receiving dexrazoxane injection, call your doctor. Dexrazoxane may harm the fetus.
  • tell your doctor if you are breastfeeding. You should not breastfeed while you are receiving dexrazoxane (Zinecard) injections. If you are receiving dexrazoxane injection (Totect), you should not breastfeed while you are receiving treatment and for 2 weeks after your final dose.
  • you should know that this medication may decrease fertility in men. Talk to your doctor about the risks of receiving dexrazoxane injections.
  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving a dexrazoxane injection.
  • you should know that treatment with dexrazoxane injection decreases but does not eliminate the risk that doxorubicin will damage your heart. Your doctor will still need to monitor you carefully to see how doxorubicin has affected your heart.

References

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
  2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020212s013lbl.pdf
  3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022025s015lbl.pdf
  4. https://www.cancer.gov/about-cancer/treatment/drugs/dexrazoxanehydrochloride
  5. https://pubchem.ncbi.nlm.nih.gov/compound/Dexrazoxane
  6. https://pubchem.ncbi.nlm.nih.gov/compound/Dexrazoxane-hydrochloride
  7. https://go.drugbank.com/drugs/DB00380
  8. https://medlineplus.gov/druginfo/meds/a609010.html
  9. https://en.wikipedia.org/wiki/Dexrazoxane
  10. https://www.ncbi.nlm.nih.gov/books/NBK560559/
  11. https://www.drugs.com/mtm/dexrazoxane.html
  12. https://www.webmd.com/drugs/2/drug-11480/dexrazoxane-hcl-intravenous/details/list-contraindications
  13. ChemIDplus
    https://www.nlm.nih.gov/copyright.html
    https://chem.nlm.nih.gov/chemidplus/sid/0024584096
    https://chem.nlm.nih.gov/chemidplus/
  14. DrugBank
    https://www.drugbank.ca/legal/terms_of_use
    Dexrazoxane
    https://www.drugbank.ca/drugs/DB00380
  15. DTP/NCI
    https://www.cancer.gov/policies/copyright-reuse
    Dexrazoxane
    https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=169780
  16. EPA DSSTox
    LICENSE
    https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
    Dexrazone
    https://comptox.epa.gov/dashboard/DTXSID3040647
    CompTox Chemicals Dashboard Chemical Lists
    https://comptox.epa.gov/dashboard/chemical-lists/
  17. European Chemicals Agency (ECHA)
    https://echa.europa.eu/web/guest/legal-notice
    https://echa.europa.eu/information-on-chemicals
    https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/168280
  18. FDA Global Substance Registration System (GSRS)
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    DEXRAZOXANE
    https://gsrs.ncats.nih.gov/ginas/app/beta/substances/048L81261F
  19. Hazardous Substances Data Bank (HSDB)
    DEXRAZOXANE
    https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7319
  20. Human Metabolome Database (HMDB)
    http://www.hmdb.ca/citing
    Dexrazoxane
    http://www.hmdb.ca/metabolites/HMDB0014524
  21. ChEBI
    (+)-dexrazoxane
    http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50223
    ChEBI Ontology
    http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
  22. FDA Pharm Classes
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    DEXRAZOXANE
    https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm
    FDA Pharmacological Classification
    https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
  23. NCI Thesaurus (NCIt)
    https://www.cancer.gov/policies/copyright-reuse
    https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1333
    NCI Thesaurus Tree
    https://ncit.nci.nih.gov
  24. ChEMBL
    http://www.ebi.ac.uk/Information/termsofuse.html
    https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1738/
    https://www.ebi.ac.uk/chembl/g/#browse/targets
  25. Comparative Toxicogenomics Database (CTD)
    http://ctdbase.org/about/legal.jsp
    Dexrazoxane
    https://ctdbase.org/detail.go?type=chem&acc=D064730
  26. Drug Gene Interaction database (DGIdb)
    http://www.dgidb.org/downloads
    DEXRAZOXANE
    https://www.dgidb.org/drugs/DEXRAZOXANE
  27. Therapeutic Target Database (TTD)
    Dexrazoxane
    http://idrblab.net/ttd/data/drug/details/D07XVN
  28. ClinicalTrials.gov
    https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
    https://clinicaltrials.gov/
  29. Drug Induced Liver Injury Rank (DILIrank) Dataset
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    dexrazoxane
    https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset
  30. European Medicines Agency (EMA)
    https://www.ema.europa.eu/en/about-us/legal-notice
    Savene (EMEA/H/C/000682)
    https://www.ema.europa.eu/en/medicines/human/EPAR/savene
  31. NCI Investigational Drugs
    LICENSE
    https://www.cancer.gov/policies/copyright-reuse
    ADR-529
    http://dtp.nci.nih.gov/NCI-InvestigationalDrugsCI92/169780%20(1992).txt
  32. Drugs and Lactation Database (LactMed)
    LICENSE
    https://www.nlm.nih.gov/copyright.html
    Dexrazoxane
    https://www.ncbi.nlm.nih.gov/books/NBK500970/
  33. EU Clinical Trials Register
    https://www.clinicaltrialsregister.eu/
  34. FDA Orange Book
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
  35. WHO Anatomical Therapeutic Chemical (ATC) Classification
    https://www.whocc.no/copyright_disclaimer/
    https://www.whocc.no/atc/
    ATC Code
    https://www.whocc.no/atc_ddd_index/
  36. National Drug Code (NDC) Directory
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    DEXRAZOXANE
    https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
  37. NCI Cancer Drugs
    LICENSE
    https://www.cancer.gov/policies/copyright-reuse
    Dexrazoxane Hydrochloride
    https://www.cancer.gov/about-cancer/treatment/drugs/dexrazoxanehydrochloride
  38. NLM RxNorm Terminology
    https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
    dexrazoxane
    https://rxnav.nlm.nih.gov/id/rxnorm/42736
  39. Springer Nature
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=19053893-732567483
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=19053893-732550760
  40. Thieme Chemistry
    https://creativecommons.org/licenses/by-nc-nd/4.0/
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=19053893-732567483
  41. Wikidata
    https://creativecommons.org/publicdomain/zero/1.0/
    Dexrazoxane
    https://www.wikidata.org/wiki/Q524995
  42. Medical Subject Headings (MeSH)
    https://www.nlm.nih.gov/copyright.html
    Dexrazoxane
    https://www.ncbi.nlm.nih.gov/mesh/68064730
    MeSH Tree
    http://www.nlm.nih.gov/mesh/meshhome.html
    Topoisomerase II Inhibitors
    https://www.ncbi.nlm.nih.gov/mesh/68059005
    Antineoplastic Agents
    https://www.ncbi.nlm.nih.gov/mesh/68000970
    Cardiotonic Agents
    https://www.ncbi.nlm.nih.gov/mesh/68002316
  43. PubChem
    https://pubchem.ncbi.nlm.nih.gov
  44. KEGG
    https://www.kegg.jp/kegg/legal.html
    Therapeutic category of drugs in Japan
    http://www.genome.jp/kegg-bin/get_htext?br08301.keg
    USP drug classification
    http://www.genome.jp/kegg-bin/get_htext?br08302.keg
    Anatomical Therapeutic Chemical (ATC) classification
    http://www.genome.jp/kegg-bin/get_htext?br08303.keg
    Target-based classification of drugs
    http://www.genome.jp/kegg-bin/get_htext?br08310.keg
  45. UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)
    GHS Classification Tree
    http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
  46. NORMAN Suspect List Exchange
    LICENSE
    Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0
    https://creativecommons.org/licenses/by/4.0/
    NORMAN Suspect List Exchange Classification
    https://www.norman-network.com/nds/SLE/
  47. PATENTSCOPE (WIPO)
    SID 388674941
    https://pubchem.ncbi.nlm.nih.gov/substance/388674941
  48. NCBI
    https://www.ncbi.nlm.nih.gov/projects/linkout

 

RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Dexrazoxane Hydrochloride – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action The mechanism by which dexrazoxane exerts its cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of EDTA that readily penetrates cell membranes. Results of laboratory studies suggest that dexrazoxane (a prodrug) is converted intracellularly to a ring-opened bidentate chelating agent that chelates to free iron and interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy. It should be noted that dexrazoxane may also be protected through its inhibitory effect on topoisomerase II. or The mechanism of action of dexrazoxane's cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of ethylenediamine tetra-acetic acid (EDTA) that readily penetrates cell membranes. Laboratory studies suggest that dexrazoxane is converted intracellularly to a ring-opened chelating agent that interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy. Dexrazoxane is a cardioprotective agent for use in conjunction with doxorubicin indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose. Patients receiving anthracycline-derivative antineoplastic agents may experience three types of cardiotoxicity: acute transient type; chronic, subacute type (related to cumulative dose and has a more indolent onset later on); and a late-onset type that manifests years after therapy, mainly in patients that have been exposed to the drug as a child. Although the exact mechanism of anthracycline-induced cardiotoxicity is not known, it has been shown to exert a variety of actions that may result in the development of cardiotoxicity. In animals, anthracyclines cause a selective inhibition of cardiac muscle gene expression for α-actin, troponin, myosin light-chain 2, and the M isoform of creatine kinase. This may lead to myofibrillar loss associated with anthracycline-induced cardiotoxicity. Anthracyclines may also cause myocyte damage via calcium overload, altered myocardial adrenergic function, the release of vasoactive amines, and proinflammatory cytokines. Furthermore, it has been suggested that the main cause of anthracycline-induced cardiotoxicity is associated with free-radical damage to DNA. The drugs intercalate DNA, chelate metal ions to produce drug-metal complexes, and generate superoxide radicals via oxidation-reduction reactions. Anthracyclines also contain a quinone structure that can undergo reduction via NADPH-dependent reactions to produce a semiquinone free radical that initiates a cascade of superoxide and hydroxide radical generation. Chelation of metal ions, particularly iron, by anthracyclines results in an anthracycline-metal complex that catalyzes the generation of reactive oxygen free radicals. This complex is a powerful oxidant that can initiate lipid peroxidation in the absence of oxygen free radicals. The toxicity induced by anthracyclines may be exacerbated in cardiac cells, as these cells do not possess sufficient amounts of certain enzymes (e.g., superoxide dismutase, catalase, glutathione peroxidase) involved in detoxifying free radicals and protecting the cells from subsequent damage. Indications For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines. Save is indicated for the treatment of anthracycline extravasation. Dexrazoxane is indicated for reducing the incidence and severity of cardiomyopathy associated with the administration of doxorubicin in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/sq m of the body surface and who would benefit from continued therapy with doxorubicin. Accidental extravasation of chemotherapy containing anthracycline often causes mutilating complications as a result of extensive tissue necrosis. Treatment, therefore, consists of extensive surgical debridement. Reducing incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin. FDA-approved indications: Reduction of incidence and severity of cardiac dysfunction associated with anthracycline use. Dexrazoxane can also be used to treat tissue damage caused by anthracyclines when they leak from the vein while being administered. Non-FDA-approved indication: Although a study is still underway as of this writing, dexrazoxane may act as a beneficial neuroprotectant to treat neurodegeneration in patients with Parkinson's disease.[rx] Use in Cancer Dexrazoxane hydrochloride is approved to treat severe side effects caused by certain types of chemotherapy. It is used to treat the following: Cardiac (heart) side effects caused by doxorubicin hydrochloride in women being treated for metastatic breast cancer. Dexrazoxane hydrochloride helps make the side effects happen less often and makes them less severe when they do occur. It is used only in women who have already received high doses of doxorubicin and continue to be treated with it. This use is approved for the Totect and Zinecard brands of dexrazoxane hydrochloride. Extravasation caused by intravenous anthracyclines. Extravasation occurs when injected drugs leak out of the vein, into the surrounding tissue. This can cause redness, pain, and swelling, and may damage the tissue. This use is approved for the Totect brand of dexrazoxane hydrochloride. Contraindications decreased blood platelets low levels of white blood cells low levels of a type of white blood cell called neutrophils pregnancy a patient who is producing milk and breastfeeding chronic kidney disease stage 3B (moderate) chronic kidney disease stage 4 (severe) chronic kidney disease stage 5 (failure) kidney disease with likely reduction in kidney function Dosage  Strengths: 250 mg; 500 mg Cardiomyopathy Prophylaxis The dosage ratio of dexrazoxane to doxorubicin is 10:1 (e.g. 500 mg/m2 dexrazoxane to 50 mg/m2 doxorubicin) Administer via IV infusion over 15 minutes. DO NOT administer via IV push. Administer doxorubicin within 30 minutes of completion of dexrazoxane infusion; do not administer doxorubicin before dexrazoxane. Do not use it with the initiation of doxorubicin therapy. Extravasation Recommended doses: Day one: 1000 mg/m2 IV over 1 to 2 hours Day two: 1000 mg/m2 IV over 1 to 2 hours Day three: 500 mg/m2 IV over 1 to 2 hours Maximum doses: Day one: 2000 mg Day two: 2000 mg Day three: 1000 mg The product must be diluted with 50 mL of 0.167 M sodium lactate injection solution prior to administration. Initiate the first infusion as soon as possible and within the first 6 hours of extravasation. Start day 2 and 3 treatments at the same hour as the first day (give or take 3 hours). Remove cooling features such as ice packs (if used) at least 15 minutes before administration to allow sufficient blood flow to the extravasation area. Side Effects The Most Common pain or swelling in the place where the medication was injected nausea vomiting diarrhea constipation stomach pain loss of appetite dizziness headache excessive tiredness difficulty falling asleep or staying asleep depression swelling of the arms, hands, feet, ankles, or lower legs sore throat, fever, chills, cough, and other signs of infection unusual bruising or bleeding pale skin weakness shortness of breath rash itching hives difficulty breathing or swallowing swelling of the eyes, face, mouth, lips, tongue, or throat dizziness fainting More common Blurred or double vision diarrhea difficulty having a bowel movement difficulty in swallowing difficulty in walking discouragement dizziness drooping eyelids fainting feeling sad or empty hair loss headache heartburn irritability jaw pain lack or loss of appetite lightheadedness loss of interest or pleasure muscle pain, spasms, cramps, or stiffness nausea numbness or tingling in the fingers and toes pain in the fingers and toes pain in the testicles pain or burning in the throat pain or redness at the site of injection pale skin at the site of injection rapid, shallow breathing stomach pain swelling or inflammation of the mouth thinning of the hair trouble concentrating trouble sleeping vomiting weight loss Rare Bluish color changes in skin color chest pain or tightness chills cold hands and feet cough fever hoarseness lower back or side pain pain, redness, or swelling in the arm or leg painful or difficult urination pale skin sneezing sore throat swelling of the hands, ankles, feet, or lower legs tenderness trouble breathing unusual bleeding or bruising unusual tiredness or weakness Black, tarry stools chest discomfort fast, irregular, or pounding heartbeat pain at the injection site ulcers, sores, or white spots in the mouth Drug Interactions DRUG INTERACTION Abacavir Dexrazoxane may decrease the excretion rate of Abacavir which could result in a higher serum level. Abatacept The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Abatacept. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Dexrazoxane. Aceclofenac Aceclofenac may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Dexrazoxane. Acetaminophen Acetaminophen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Dexrazoxane. Aclidinium Dexrazoxane may decrease the excretion rate of Aclidinium which could result in a higher serum level. Acrivastine Dexrazoxane may decrease the excretion rate of Acrivastine which could result in a higher serum level. Acyclovir Acyclovir may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Dexrazoxane. Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Adenovirus The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Dexrazoxane. Albutrepenonacog Dexrazoxane may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level. Alclofenac Alclofenac may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dexrazoxane. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Dexrazoxane. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dexrazoxane. Allogeneic The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Dexrazoxane. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Dexrazoxane. Almasilate Dexrazoxane may decrease the excretion rate of Almasilate which could result in a higher serum level. Almotriptan Dexrazoxane may decrease the excretion rate of Almotriptan which could result in a higher serum level. Alogliptin Dexrazoxane may decrease the excretion rate of Alogliptin which could result in a higher serum level. Alprazolam Dexrazoxane may decrease the excretion rate of Alprazolam which could result in a higher serum level. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Dexrazoxane. Altretamine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Altretamine. Amantadine Dexrazoxane may decrease the excretion rate of Amantadine which could result in a higher serum level. Amikacin Dexrazoxane may decrease the excretion rate of Amikacin which could result in a higher serum level. Amiloride Amiloride may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Aminophenazone Aminophenazone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Amitriptyline Amitriptyline may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Ammonium chloride Dexrazoxane may decrease the excretion rate of Ammonium chloride which could result in a higher serum level. Amoxicillin Dexrazoxane may decrease the excretion rate of Amoxicillin which could result in a higher serum level. Amphetamine Amphetamine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Amphotericin B Amphotericin B may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Ampicillin Dexrazoxane may decrease the excretion rate of Ampicillin which could result in a higher serum level. Amrinone Dexrazoxane may decrease the excretion rate of Amrinone which could result in a higher serum level. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Dexrazoxane. Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Dexrazoxane. Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Dexrazoxane. Ancestim Dexrazoxane may decrease the excretion rate of Ancestim which could result in a higher serum level. Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Dexrazoxane. Anifrolumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Anifrolumab. Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Dexrazoxane. Anthrax immune The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Dexrazoxane. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Dexrazoxane. Antihemophilic Dexrazoxane may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level. antilymphocyte The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Antilymphocyte immunoglobulin (horse). Antipyrine Antipyrine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Dexrazoxane. Antithrombin III human Dexrazoxane may decrease the excretion rate of Antithrombin III human which could result in a higher serum level. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dexrazoxane. Antrafenine Antrafenine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Apalutamide Dexrazoxane may decrease the excretion rate of Apalutamide which could result in a higher serum level. Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Dexrazoxane. Apremilast The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Apremilast. Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Dexrazoxane. Arformoterol Dexrazoxane may decrease the excretion rate of Arformoterol which could result in a higher serum level. Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Dexrazoxane. Arsenic trioxide The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Arsenic trioxide. COVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Dexrazoxane. Atazanavir Atazanavir may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Atomoxetine Atomoxetine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Auranofin Dexrazoxane may decrease the excretion rate of Auranofin which could result in a higher serum level. Aurothioglucose Dexrazoxane may decrease the excretion rate of Aurothioglucose which could result in a higher serum level. Azacitidine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Azacitidine. Azathioprine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Azathioprine. Azelaic acid Dexrazoxane may decrease the excretion rate of Azelaic acid which could result in a higher serum level. Aztreonam Aztreonam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Bacillus antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Dexrazoxane. Bacillus calmette The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Dexrazoxane. Bacillus antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Dexrazoxane. Bacitracin Bacitracin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Baclofen Baclofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Balsalazide Balsalazide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Baricitinib The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Dexrazoxane. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Dexrazoxane. Beclomethasone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Beclomethasone dipropionate. Belatacept The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Belinostat. Belumosudil The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Belumosudil. Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Dexrazoxane. Bendamustine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Bendamustine. Bendroflumethiazide Bendroflumethiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Benorilate Benorilate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Benoxaprofen Benoxaprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Benserazide Dexrazoxane may decrease the excretion rate of Benserazide which could result in a higher serum level. Benzatropine Benzatropine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Benznidazole Dexrazoxane may decrease the excretion rate of Benznidazole which could result in a higher serum level. Benzthiazide Benzthiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Benzydamine Benzydamine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Bepotastine Dexrazoxane may decrease the excretion rate of Bepotastine which could result in a higher serum level. Betamethasone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Betamethasone. Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Dexrazoxane. Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Dexrazoxane. Bicisate Dexrazoxane may decrease the excretion rate of Bicisate which could result in a higher serum level. Bimekizumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Bimekizumab. Bismuth subgallate Dexrazoxane may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level. Bisoprolol Dexrazoxane may decrease the excretion rate of Bisoprolol which could result in a higher serum level. Bisoxatin Dexrazoxane may decrease the excretion rate of Bisoxatin which could result in a higher serum level. Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Dexrazoxane. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Dexrazoxane. Blinatumomab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Blinatumomab. Bordetella The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Dexrazoxane. Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Dexrazoxane. Bosutinib The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Bosutinib. Brentuximab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Brentuximab vedotin. Brivaracetam Dexrazoxane may decrease the excretion rate of Brivaracetam which could result in a higher serum level. Brodalumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Brodalumab. Bromazepam Dexrazoxane may decrease the excretion rate of Bromazepam which could result in a higher serum level. Bromotheophylline Bromotheophylline may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Budesonide The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Budesonide. Bumadizone Bumadizone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Bumetanide Bumetanide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Bupropion Dexrazoxane may decrease the excretion rate of Bupropion which could result in a higher serum level. Buspirone Dexrazoxane may decrease the excretion rate of Buspirone which could result in a higher serum level. Busulfan The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Busulfan. Butabarbital Butabarbital may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cabazitaxel The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cabazitaxel. Canagliflozin Canagliflozin may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Canakinumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Canakinumab. Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Dexrazoxane. Canrenoic acid Canrenoic acid may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Capecitabine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Capecitabine. Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Dexrazoxane. Capreomycin Dexrazoxane may decrease the excretion rate of Capreomycin which could result in a higher serum level. Carbamazepine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Carbamazepine. Carbidopa Carbidopa may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Carboplatin The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Carboplatin. Carfilzomib The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Carfilzomib. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Dexrazoxane. Carprofen Carprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefaclor Cefaclor may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefadroxil Cefadroxil may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefalotin Cefalotin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefamandole Cefamandole may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefapirin Cefapirin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefazolin Cefazolin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefdinir Dexrazoxane may decrease the excretion rate of Cefdinir which could result in a higher serum level. Cefditoren Cefditoren may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefepime Cefepime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefmenoxime Cefmenoxime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefmetazole Cefmetazole may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefonicid Cefonicid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefoperazone Cefoperazone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Ceforanide Ceforanide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefotaxime Cefotaxime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefotetan Cefotetan may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefotiam Cefotiam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefoxitin Cefoxitin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefpiramide Cefpiramide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefpirome Cefpirome may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefpodoxime Cefpodoxime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefprozil Cefprozil may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefradine Cefradine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Ceftaroline fosamil Ceftaroline fosamil may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Ceftazidime Ceftazidime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Ceftibuten Ceftibuten may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Ceftizoxime Ceftizoxime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Ceftobiprole Ceftobiprole may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Ceftolozane Dexrazoxane may decrease the excretion rate of Ceftolozane which could result in a higher serum level. Ceftriaxone Ceftriaxone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cefuroxime Cefuroxime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Celecoxib Celecoxib may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cephalexin Cephalexin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cephaloglycin Cephaloglycin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Certolizumab pegol The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Certolizumab pegol. Cetirizine Cetirizine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cevimeline Cevimeline may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Chloral hydrate Dexrazoxane may decrease the excretion rate of Chloral hydrate which could result in a higher serum level. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Dexrazoxane. Chloramphenicol The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Chloramphenicol. Chloroquine Dexrazoxane may decrease the excretion rate of Chloroquine which could result in a higher serum level. Chlorothiazide Chlorothiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Chloroxylenol Dexrazoxane may decrease the excretion rate of Chloroxylenol which could result in a higher serum level. Chlorpromazine Dexrazoxane may decrease the excretion rate of Chlorpromazine which could result in a higher serum level. Chlorpropamide Dexrazoxane may decrease the excretion rate of Chlorpropamide which could result in a higher serum level. Chlorthalidone Chlorthalidone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Chlorzoxazone Chlorzoxazone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Choline C 11 Dexrazoxane may decrease the excretion rate of Choline C 11 which could result in a higher serum level. Choline magnesium Choline magnesium trisalicylate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Choline salicylate Dexrazoxane may decrease the excretion rate of Choline salicylate which could result in a higher serum level. Chondroitin sulfate Dexrazoxane may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level. Chromic chloride Dexrazoxane may decrease the excretion rate of Chromic chloride which could result in a higher serum level. Chromic nitrate Dexrazoxane may decrease the excretion rate of Chromic nitrate which could result in a higher serum level. Chromium Dexrazoxane may decrease the excretion rate of Chromium which could result in a higher serum level. Chromium gluconate Dexrazoxane may decrease the excretion rate of Chromium gluconate which could result in a higher serum level. Chromium nicotinate Dexrazoxane may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level. Chromous sulfate Dexrazoxane may decrease the excretion rate of Chromous sulfate which could result in a higher serum level. Ciclesonide The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ciclesonide. Cidofovir Cidofovir may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Cilostazol The risk or severity of bleeding can be increased when Cilostazol is combined with Dexrazoxane. Cimetidine Dexrazoxane may decrease the excretion rate of Cimetidine which could result in a higher serum level. Ciprofloxacin Dexrazoxane may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level. Cisplatin The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cisplatin. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Dexrazoxane. Clevidipine Dexrazoxane may decrease the excretion rate of Clevidipine which could result in a higher serum level. Clobazam Clobazam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Clobetasol propionate The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Clobetasol propionate. Clofarabine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Clofarabine. Clomipramine Dexrazoxane may decrease the excretion rate of Clomipramine which could result in a higher serum level. Clonazepam Dexrazoxane may decrease the excretion rate of Clonazepam which could result in a higher serum level. Clopidogrel The risk or severity of bleeding can be increased when Clopidogrel is combined with Dexrazoxane. Clorazepic acid Dexrazoxane may decrease the excretion rate of Clorazepic acid which could result in a higher serum level. Clostridium The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dexrazoxane. Clove oil Dexrazoxane may decrease the excretion rate of Clove oil which could result in a higher serum level. Clozapine The risk or severity of neutropenia can be increased when Dexrazoxane is combined with Clozapine. Colchicine Dexrazoxane may decrease the excretion rate of Colchicine which could result in a higher serum level. Colistimethate Colistimethate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Colistin Dexrazoxane may decrease the excretion rate of Colistin which could result in a higher serum level. Conivaptan Conivaptan may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Conjugated estrogens Conjugated estrogens may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Corifollitropin alfa Dexrazoxane may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level. Corticotropin The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Corticotropin. Cortisone acetate The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cortisone acetate. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dexrazoxane. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dexrazoxane. Cyclopenthiazide Cyclopenthiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Cyclophosphamide The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cyclophosphamide. Cyclosporine Dexrazoxane may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide Cyclothiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Cytarabine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cytarabine. Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Dexrazoxane. Dabigatran etexilate Dexrazoxane may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level. Dacarbazine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dacarbazine. Dactinomycin The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dactinomycin. Dalfampridine Dexrazoxane may decrease the excretion rate of Dalfampridine which could result in a higher serum level. Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Dexrazoxane. Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Dexrazoxane. Dapagliflozin Dapagliflozin may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Daptomycin Daptomycin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Dasatinib The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dasatinib. Daunorubicin The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Daunorubicin. Decitabine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Decitabine. Deferiprone Dexrazoxane may decrease the excretion rate of Deferiprone which could result in a higher serum level. Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Dexrazoxane. Deflazacort The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Deflazacort. Delafloxacin Dexrazoxane may decrease the excretion rate of Delafloxacin which could result in a higher serum level. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Dexrazoxane. Desipramine Dexrazoxane may decrease the excretion rate of Desipramine which could result in a higher serum level. Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Dexrazoxane. Desmopressin Desmopressin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Desoximetasone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Desoximetasone. Desvenlafaxine Dexrazoxane may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level. Deucravacitinib The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Deucravacitinib. Deutetrabenazine Dexrazoxane may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level. Dexamethasone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dexamethasone. Dexibuprofen Dexibuprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Dexketoprofen Dexketoprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Dexmedetomidine Dexrazoxane may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level. Dexpanthenol Dexrazoxane may decrease the excretion rate of Dexpanthenol which could result in a higher serum level. Dextran Dexrazoxane may decrease the excretion rate of Dextran which could result in a higher serum level. Diatrizoate Diatrizoate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Diazepam Dexrazoxane may decrease the excretion rate of Diazepam which could result in a higher serum level. Dichlorobenzyl Dexrazoxane may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level. Diclofenac Diclofenac may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Diclofenamide Diclofenamide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Dexrazoxane. Dicyclomine Dexrazoxane may decrease the excretion rate of Dicyclomine which could result in a higher serum level. Didanosine Dexrazoxane may decrease the excretion rate of Didanosine which could result in a higher serum level. Dienogest Dexrazoxane may decrease the excretion rate of Dienogest which could result in a higher serum level. Diflunisal Diflunisal may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Difluocortolone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Difluocortolone. Digoxin Dexrazoxane may decrease the excretion rate of Digoxin which could result in a higher serum level. Dihydrostreptomycin Dihydrostreptomycin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Dimercaprol Dexrazoxane may decrease the excretion rate of Dimercaprol which could result in a higher serum level. Dimethyl fumarate The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dimethyl fumarate. Dimethyl sulfoxide The therapeutic efficacy of Dexrazoxane can be decreased when used in combination with Dimethyl sulfoxide. Dinutuximab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dinutuximab. Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Dexrazoxane. Diroximel fumarate The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Diroximel fumarate. Disopyramide Disopyramide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. DMethylephedrine Dexrazoxane may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level. Dobutamine Dexrazoxane may decrease the excretion rate of Dobutamine which could result in a higher serum level. Docetaxel The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Docetaxel. Dopamine Dexrazoxane may decrease the excretion rate of Dopamine which could result in a higher serum level. Doripenem Dexrazoxane may decrease the excretion rate of Doripenem which could result in a higher serum level. Doxacurium Dexrazoxane may decrease the excretion rate of Doxacurium which could result in a higher serum level. Doxepin Dexrazoxane may decrease the excretion rate of Doxepin which could result in a higher serum level. Doxorubicin The therapeutic efficacy of Doxorubicin can be decreased when used in combination with Dexrazoxane. Doxycycline Doxycycline may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Drospirenone Drospirenone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dexrazoxane. Droxidopa Dexrazoxane may decrease the excretion rate of Droxidopa which could result in a higher serum level. Duloxetine Dexrazoxane may decrease the excretion rate of Duloxetine which could result in a higher serum level. Dyphylline Dexrazoxane may decrease the excretion rate of Dyphylline which could result in a higher serum level. Ebola Zaire] The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Dexrazoxane. Eculizumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Eculizumab. Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Dexrazoxane. Edoxaban Dexrazoxane may decrease the excretion rate of Edoxaban which could result in a higher serum level. Edrophonium Dexrazoxane may decrease the excretion rate of Edrophonium which could result in a higher serum level. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Dexrazoxane. Emapalumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Emapalumab. Enalaprilat Dexrazoxane may decrease the excretion rate of Enalaprilat which could result in a higher serum level. Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Dexrazoxane. Enzalutamide Dexrazoxane may decrease the excretion rate of Enzalutamide which could result in a higher serum level. Epirubicin The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Epirubicin. Eplerenone Eplerenone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Dexrazoxane. Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Dexrazoxane. Eribulin The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Eribulin. Ertapenem Ertapenem may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Ertugliflozin Ertugliflozin may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Estazolam Dexrazoxane may decrease the excretion rate of Estazolam which could result in a higher serum level. Estradiol Dexrazoxane may decrease the excretion rate of Estradiol which could result in a higher serum level. Estradiol acetate Dexrazoxane may decrease the excretion rate of Estradiol acetate which could result in a higher serum level. Estradiol cypionate Dexrazoxane may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level. Estradiol dienanthate Dexrazoxane may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level. Estradiol valerate Dexrazoxane may decrease the excretion rate of Estradiol valerate which could result in a higher serum level. Estramustine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Estramustine. Estrone sulfate Dexrazoxane may decrease the excretion rate of Estrone sulfate which could result in a higher serum level. Eszopiclone Dexrazoxane may decrease the excretion rate of Eszopiclone which could result in a higher serum level. Etacrynic acid Etacrynic acid may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Etafedrine Dexrazoxane may decrease the excretion rate of Etafedrine which could result in a higher serum level. Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Dexrazoxane. Ethambutol Ethambutol may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Etodolac Etodolac may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Etomidate Etomidate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Etonogestrel Etonogestrel may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Etoposide The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Etoposide. Etoricoxib Etoricoxib may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Eucalyptus oil Dexrazoxane may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level. Everolimus The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Everolimus. Ezogabine Dexrazoxane may decrease the excretion rate of Ezogabine which could result in a higher serum level. Famtozinameran The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Dexrazoxane. Fenbufen Fenbufen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Fenofibrate Dexrazoxane may decrease the excretion rate of Fenofibrate which could result in a higher serum level. Fenofibric acid Dexrazoxane may decrease the excretion rate of Fenofibric acid which could result in a higher serum level. Fenoldopam Dexrazoxane may decrease the excretion rate of Fenoldopam which could result in a higher serum level. Fenoprofen Fenoprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Fentanyl Dexrazoxane may decrease the excretion rate of Fentanyl which could result in a higher serum level. Fesoterodine Dexrazoxane may decrease the excretion rate of Fesoterodine which could result in a higher serum level. Filgotinib The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Filgotinib. Finerenone Finerenone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Fingolimod Dexrazoxane may increase the immunosuppressive activities of Fingolimod. Flavoxate Dexrazoxane may decrease the excretion rate of Flavoxate which could result in a higher serum level. Floctafenine Floctafenine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Florbetaben (18F) Dexrazoxane may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level. Florbetapir (18F) Dexrazoxane may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Dexrazoxane. Fluconazole Fluconazole may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Flucytosine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Flucytosine. Fludarabine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fludarabine. Fludeoxyglucose Dexrazoxane may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level. Fludrocortisone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fludrocortisone. Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Dexrazoxane. Flumazenil Dexrazoxane may decrease the excretion rate of Flumazenil which could result in a higher serum level. Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Dexrazoxane. Fluocinolone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluocinolone acetonide. Fluocinonide The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluocinonide. Fluocortolone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Dexrazoxane. Fluorouracil The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluorouracil. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Dexrazoxane. Fluprednisolone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluprednisolone. Flurazepam Dexrazoxane may decrease the excretion rate of Flurazepam which could result in a higher serum level. Flurbiprofen Flurbiprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Flutamide Dexrazoxane may decrease the excretion rate of Flutamide which could result in a higher serum level. Fluticasone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluticasone. Fluticasone furoate The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluticasone furoate. Fluticasone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluticasone propionate. Fluvoxamine Fluvoxamine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Folic acid Folic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Fomepizole Dexrazoxane may decrease the excretion rate of Fomepizole which could result in a higher serum level. Fondaparinux Dexrazoxane may decrease the excretion rate of Fondaparinux which could result in a higher serum level. Formestane Dexrazoxane may decrease the excretion rate of Formestane which could result in a higher serum level. Foscarnet Foscarnet may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Fosfomycin Dexrazoxane may decrease the excretion rate of Fosfomycin which could result in a higher serum level. Fosinopril Dexrazoxane may decrease the excretion rate of Fosinopril which could result in a higher serum level. Framycetin Framycetin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Furosemide Furosemide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Gabapentin enacarbil Dexrazoxane may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level. Gadobenic acid Dexrazoxane may decrease the excretion rate of Gadobenic acid which could result in a higher serum level. Gadodiamide Gadodiamide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Gadofosveset Dexrazoxane may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level. Gadopentetic acid Dexrazoxane may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level. Gadoteric acid Dexrazoxane may decrease the excretion rate of Gadoteric acid which could result in a higher serum level. Gadoteridol Dexrazoxane may decrease the excretion rate of Gadoteridol which could result in a higher serum level. Gallium nitrate The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Gallium nitrate. Ganciclovir Dexrazoxane may decrease the excretion rate of Ganciclovir which could result in a higher serum level. Gemcitabine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Gemcitabine. Gemfibrozil Dexrazoxane may decrease the excretion rate of Gemfibrozil which could result in a higher serum level. Gemtuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexrazoxane. Gentamicin Dexrazoxane may decrease the excretion rate of Gentamicin which could result in a higher serum level. Gimeracil Dexrazoxane may decrease the excretion rate of Gimeracil which could result in a higher serum level. Givosiran Givosiran may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Glatiramer The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Glatiramer. Glipizide Dexrazoxane may decrease the excretion rate of Glipizide which could result in a higher serum level. Glycerol Dexrazoxane may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level. Golimumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Golimumab. Golodirsen Dexrazoxane may decrease the excretion rate of Golodirsen which could result in a higher serum level. Goserelin Goserelin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Guanethidine Dexrazoxane may decrease the excretion rate of Guanethidine which could result in a higher serum level. Guanfacine Dexrazoxane may decrease the excretion rate of Guanfacine which could result in a higher serum level. Guselkumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Guselkumab. Hydralazine Dexrazoxane may decrease the excretion rate of Hydralazine which could result in a higher serum level. Hydrochlorothiazide Hydrochlorothiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Hydrocortisone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Hydrocortisone acetate. Hydrocortisone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Hydrocortisone butyrate. Hydrocortisone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Hydrocortisone succinate. Hydroflumethiazide Hydroflumethiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Hydromorphone Hydromorphone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Hydroxocobalamin Hydroxocobalamin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Hydroxychloroquine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Hydroxychloroquine. Hydroxyethyl Starch Dexrazoxane may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level. Hydroxyurea The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Hydroxyurea. Ibritumomab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexrazoxane. Ibrutinib The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ibrutinib. Ibuprofen Ibuprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Ibutilide Ibutilide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Icatibant Dexrazoxane may decrease the excretion rate of Icatibant which could result in a higher serum level. Icosapent Icosapent may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Dexrazoxane. Idarubicin The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Idarubicin. Idarucizumab Dexrazoxane may decrease the excretion rate of Idarucizumab which could result in a higher serum level. Idebenone Dexrazoxane may decrease the excretion rate of Idebenone which could result in a higher serum level. Idelalisib The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Idelalisib. Ifosfamide The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ifosfamide. Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Dexrazoxane. Imatinib The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Imatinib. Imipramine Dexrazoxane may decrease the excretion rate of Imipramine which could result in a higher serum level. Indapamide Indapamide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Indigotindisulf Dexrazoxane may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level. Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Dexrazoxane. Inebilizumab The risk or severity of infection can be increased when Dexrazoxane is combined with Inebilizumab. Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Dexrazoxane. othalamic acid Dexrazoxane may decrease the excretion rate of Iothalamic acid which could result in a higher serum level. Ioversol Dexrazoxane may decrease the excretion rate of Ioversol which could result in a higher serum level. Ioxilan Dexrazoxane may decrease the excretion rate of Ioxilan which could result in a higher serum level. Ipecac Dexrazoxane may decrease the excretion rate of Ipecac which could result in a higher serum level. Ipilimumab Dexrazoxane may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Irinotecan The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Irinotecan. Isoniazid Dexrazoxane may decrease the excretion rate of Isoniazid which could result in a higher serum level. Isosorbide Isosorbide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Isosorbide Dexrazoxane may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level. Isosulfan blue Dexrazoxane may decrease the excretion rate of Isosulfan blue which could result in a higher serum level. Isotretinoin Dexrazoxane may decrease the excretion rate of Isotretinoin which could result in a higher serum level. Isoxicam Isoxicam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Isradipine Isradipine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Ixabepilone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ixabepilone. Ixazomib Dexrazoxane may decrease the excretion rate of Ixazomib which could result in a higher serum level. Ixekizumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ixekizumab. COVID Vaccine The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Dexrazoxane. Japanese encephalitis The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Dexrazoxane. Kanamycin Dexrazoxane may decrease the excretion rate of Kanamycin which could result in a higher serum level. Ketamine Dexrazoxane may decrease the excretion rate of Ketamine which could result in a higher serum level. Ketazolam Dexrazoxane may decrease the excretion rate of Ketazolam which could result in a higher serum level. Ketoprofen Ketoprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Ketorolac Ketorolac may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Labetalol Dexrazoxane may decrease the excretion rate of Labetalol which could result in a higher serum level. Lamivudine Dexrazoxane may decrease the excretion rate of Lamivudine which could result in a higher serum level. Lamotrigine Dexrazoxane may decrease the excretion rate of Lamotrigine which could result in a higher serum level. Latamoxef Latamoxef may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Ledipasvir Dexrazoxane may decrease the excretion rate of Ledipasvir which could result in a higher serum level. Leflunomide The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Leflunomide. Lenalidomide The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Lenalidomide. Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Dexrazoxane. Lesinurad Dexrazoxane may decrease the excretion rate of Lesinurad which could result in a higher serum level. Leuprolide Leuprolide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Levobupivacaine Dexrazoxane may decrease the excretion rate of Levobupivacaine which could result in a higher serum level. Levocarnitine Dexrazoxane may decrease the excretion rate of Levocarnitine which could result in a higher serum level. Levocetirizine Dexrazoxane may decrease the excretion rate of Levocetirizine which could result in a higher serum level. Levofloxacin Dexrazoxane may decrease the excretion rate of Levofloxacin which could result in a higher serum level. Levosalbutamol Dexrazoxane may decrease the excretion rate of Levosalbutamol which could result in a higher serum level. Linezolid The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Linezolid. Liothyronine Liothyronine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Lipegfilgrastim Dexrazoxane may increase the myelosuppressive activities of Lipegfilgrastim. Lisinopril Dexrazoxane may decrease the excretion rate of Lisinopril which could result in a higher serum level. Lithium carbonate Dexrazoxane may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. Lithium citrate Lithium citrate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Lixisenatide Dexrazoxane may decrease the excretion rate of Lixisenatide which could result in a higher serum level. Lofexidine Dexrazoxane may decrease the excretion rate of Lofexidine which could result in a higher serum level. Lomustine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Lomustine. Lopinavir The serum concentration of Dexrazoxane can be increased when it is combined with Lopinavir. Loracarbef Loracarbef may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Lorazepam Lorazepam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Lorcaserin Dexrazoxane may decrease the excretion rate of Lorcaserin which could result in a higher serum level. Lornoxicam Lornoxicam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Lorpiprazole Dexrazoxane may decrease the excretion rate of Lorpiprazole which could result in a higher serum level. Loxoprofen Loxoprofen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Lubiprostone Dexrazoxane may decrease the excretion rate of Lubiprostone which could result in a higher serum level. Lumiracoxib Lumiracoxib may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Macitentan Dexrazoxane may decrease the excretion rate of Macitentan which could result in a higher serum level. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Dexrazoxane. Magnesium carbonate Dexrazoxane may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. Magnesium chloride Dexrazoxane may decrease the excretion rate of Magnesium chloride which could result in a higher serum level. Magnesium Dexrazoxane may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level. Magnesium Dexrazoxane may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level. Mangafodipir Dexrazoxane may decrease the excretion rate of Mangafodipir which could result in a higher serum level. Mannitol Mannitol may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Maprotiline Dexrazoxane may decrease the excretion rate of Maprotiline which could result in a higher serum level. Measles virus The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Dexrazoxane. Mecamylamine Dexrazoxane may decrease the excretion rate of Mecamylamine which could result in a higher serum level. Mechlorethamine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mechlorethamine. Meclofenamic acid Meclofenamic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Medroxyprogesterone Dexrazoxane may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level. Mefenamic acid Mefenamic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Megestrol acetate Megestrol acetate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Meloxicam Meloxicam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Melphalan The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Melphalan. Memantine Dexrazoxane may decrease the excretion rate of Memantine which could result in a higher serum level. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Dexrazoxane. Meperidine Dexrazoxane may decrease the excretion rate of Meperidine which could result in a higher serum level. Mepivacaine Dexrazoxane may decrease the excretion rate of Mepivacaine which could result in a higher serum level. Mepolizumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mepolizumab. Meprednisone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Meprednisone. Mercaptopurine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mercaptopurine. Meropenem Dexrazoxane may decrease the excretion rate of Meropenem which could result in a higher serum level. Mesalazine Mesalazine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Metamfetamine Dexrazoxane may decrease the excretion rate of Metamfetamine which could result in a higher serum level. Metamizole Metamizole may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Metaxalone Dexrazoxane may decrease the excretion rate of Metaxalone which could result in a higher serum level. Metformin Metformin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Methadone Methadone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Methazolamide Methazolamide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Methimazole The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Methimazole. Methotrexate The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Methotrexate. Methoxsalen Dexrazoxane may decrease the excretion rate of Methoxsalen which could result in a higher serum level. Methyldopa Dexrazoxane may decrease the excretion rate of Methyldopa which could result in a higher serum level. Methylene blue Dexrazoxane may decrease the excretion rate of Methylene blue which could result in a higher serum level. Methylnaltrexone Dexrazoxane may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level. Methylprednisolone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Methylprednisolone. Methyltestosterone Dexrazoxane may decrease the excretion rate of Methyltestosterone which could result in a higher serum level. Meticrane Meticrane may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Metoclopramide Dexrazoxane may decrease the excretion rate of Metoclopramide which could result in a higher serum level. Metolazone Metolazone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Metoprolol Metoprolol may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Metyrapone Dexrazoxane may decrease the excretion rate of Metyrapone which could result in a higher serum level. Midazolam Dexrazoxane may decrease the excretion rate of Midazolam which could result in a higher serum level. Migalastat Dexrazoxane may decrease the excretion rate of Migalastat which could result in a higher serum level. Milnacipran Dexrazoxane may decrease the excretion rate of Milnacipran which could result in a higher serum level. Milrinone Milrinone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Mirabegron Dexrazoxane may decrease the excretion rate of Mirabegron which could result in a higher serum level. Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Dexrazoxane. Mitoxantrone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mitoxantrone. COVID-19 Vaccine The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Dexrazoxane. Modified vaccinia The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Dexrazoxane. Mometasone furoate The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mometasone furoate. Monomethyl fumarate The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Monomethyl fumarate. Mosunetuzumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mosunetuzumab. Moxisylyte Dexrazoxane may decrease the excretion rate of Moxisylyte which could result in a higher serum level. Mumps virus The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Dexrazoxane. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Dexrazoxane. Muzolimine Muzolimine may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Mycophenolate The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mycophenolate mofetil. Mycophenolic acid The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mycophenolic acid. N-acetyltyrosine Dexrazoxane may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level. Nabumetone Nabumetone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Nadolol Dexrazoxane may decrease the excretion rate of Nadolol which could result in a higher serum level. Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Dexrazoxane. Naldemedine Dexrazoxane may decrease the excretion rate of Naldemedine which could result in a higher serum level. Nalmefene Dexrazoxane may decrease the excretion rate of Nalmefene which could result in a higher serum level. Naloxone Dexrazoxane may decrease the excretion rate of Naloxone which could result in a higher serum level. Naproxen Naproxen may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Natalizumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Natalizumab. Nateglinide Dexrazoxane may decrease the excretion rate of Nateglinide which could result in a higher serum level. Nedaplatin Dexrazoxane may decrease the excretion rate of Nedaplatin which could result in a higher serum level. Nedocromil Dexrazoxane may decrease the excretion rate of Nedocromil which could result in a higher serum level. Nefazodone Dexrazoxane may decrease the excretion rate of Nefazodone which could result in a higher serum level. Nelarabine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Nelarabine. Neomycin Dexrazoxane may decrease the excretion rate of Neomycin which could result in a higher serum level. Netilmicin Dexrazoxane may decrease the excretion rate of Netilmicin which could result in a higher serum level. Nicorandil Dexrazoxane may decrease the excretion rate of Nicorandil which could result in a higher serum level. Nifedipine Dexrazoxane may decrease the excretion rate of Nifedipine which could result in a higher serum level. Nilotinib The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Nilotinib. Nilutamide Dexrazoxane may decrease the excretion rate of Nilutamide which could result in a higher serum level. Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Dexrazoxane. Nisoldipine Dexrazoxane may decrease the excretion rate of Nisoldipine which could result in a higher serum level. Nitric Oxide Dexrazoxane may decrease the excretion rate of Nitric Oxide which could result in a higher serum level. Nitrofurantoin Dexrazoxane may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. Nitroprusside Nitroprusside may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Dexrazoxane. Obinutuzumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Dexrazoxane. Octinoxate Dexrazoxane may decrease the excretion rate of Octinoxate which could result in a higher serum level. Ofatumumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ofatumumab. Olaparib The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Olaparib. Olsalazine Olsalazine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Opium Dexrazoxane may decrease the excretion rate of Opium which could result in a higher serum level. Oseltamivir Oseltamivir may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Oxacillin Dexrazoxane may decrease the excretion rate of Oxacillin which could result in a higher serum level. Oxaliplatin The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Oxaliplatin. Oxaprozin Oxaprozin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Oxazepam Dexrazoxane may decrease the excretion rate of Oxazepam which could result in a higher serum level. Oxybenzone Dexrazoxane may decrease the excretion rate of Oxybenzone which could result in a higher serum level. Oxyphenbutazone Oxyphenbutazone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Oxyquinoline Dexrazoxane may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. Ozanimod The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ozanimod. Paclitaxel The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Paclitaxel. Palbociclib The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Dexrazoxane. Paliperidone Dexrazoxane may decrease the excretion rate of Paliperidone which could result in a higher serum level. Palonosetron Palonosetron may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Pamidronic acid Pamidronic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Panobinostat The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Panobinostat. Pantoprazole Pantoprazole may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Parecoxib Parecoxib may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Dexrazoxane. Paromomycin Paromomycin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Patent Blue Dexrazoxane may decrease the excretion rate of Patent Blue which could result in a higher serum level. Pazopanib The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pazopanib. Pegaptanib Dexrazoxane may decrease the excretion rate of Pegaptanib which could result in a higher serum level. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dexrazoxane. Pegcetacoplan The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pegcetacoplan. Peginesatide Dexrazoxane may decrease the excretion rate of Peginesatide which could result in a higher serum level. Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dexrazoxane. Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Dexrazoxane. Peginterferon beta-1a The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pemetrexed. Penbutolol Dexrazoxane may decrease the excretion rate of Penbutolol which could result in a higher serum level. Penicillamine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Penicillamine. Pentaerythritol Dexrazoxane may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level. Pentamidine Pentamidine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Pentastarch Dexrazoxane may decrease the excretion rate of Pentastarch which could result in a higher serum level. Pentetic acid Dexrazoxane may decrease the excretion rate of Pentetic acid which could result in a higher serum level. Pentobarbital Pentobarbital may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Dexrazoxane. Pentostatin The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pentostatin. Pentoxifylline The risk or severity of bleeding can be increased when Pentoxifylline is combined with Dexrazoxane. Perindopril Dexrazoxane may decrease the excretion rate of Perindopril which could result in a higher serum level. Permethrin Dexrazoxane may decrease the excretion rate of Permethrin which could result in a higher serum level. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Dexrazoxane. Phenazopyridine Phenazopyridine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Phenelzine Dexrazoxane may decrease the excretion rate of Phenelzine which could result in a higher serum level. Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Dexrazoxane. Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Dexrazoxane. Phentolamine Dexrazoxane may decrease the excretion rate of Phentolamine which could result in a higher serum level. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dexrazoxane. Phenylbutazone Phenylbutazone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Pholcodine Dexrazoxane may decrease the excretion rate of Pholcodine which could result in a higher serum level. Phosphoric acid Dexrazoxane may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. Phylloquinone Dexrazoxane may decrease the excretion rate of Phylloquinone which could result in a higher serum level. Picosulfuric acid Dexrazoxane may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dexrazoxane. Pindolol Dexrazoxane may decrease the excretion rate of Pindolol which could result in a higher serum level. Piperacillin Piperacillin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Piracetam Dexrazoxane may decrease the excretion rate of Piracetam which could result in a higher serum level. Piretanide Piretanide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Pirfenidone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pirfenidone. Piroxicam Piroxicam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Pitolisant Dexrazoxane may decrease the excretion rate of Pitolisant which could result in a higher serum level. Plazomicin Dexrazoxane may decrease the excretion rate of Plazomicin which could result in a higher serum level. Plerixafor Dexrazoxane may decrease the excretion rate of Plerixafor which could result in a higher serum level. Polythiazide Polythiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Pomalidomide The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pomalidomide. Ponatinib The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ponatinib. Ponesimod The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ponesimod. Potassium Potassium may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Potassium acetate Dexrazoxane may decrease the excretion rate of Potassium acetate which could result in a higher serum level. Potassium bicarbonate Dexrazoxane may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level. Potassium cation Potassium cation may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Potassium Dexrazoxane may decrease the excretion rate of Potassium chloride which could result in a higher serum level. Potassium citrate Potassium citrate may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Potassium nitrate Dexrazoxane may decrease the excretion rate of Potassium nitrate which could result in a higher serum level. Potassium Dexrazoxane may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level. Potassium sulfate Dexrazoxane may decrease the excretion rate of Potassium sulfate which could result in a higher serum level. Pralatrexate The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pralatrexate. Pralidoxime Dexrazoxane may decrease the excretion rate of Pralidoxime which could result in a higher serum level. Pramipexole Dexrazoxane may decrease the excretion rate of Pramipexole which could result in a higher serum level. Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Dexrazoxane. Prednisolone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Prednisolone. Prednisone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Prednisone. Pregabalin Pregabalin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Probenecid Dexrazoxane may decrease the excretion rate of Probenecid which could result in a higher serum level. Procainamide Dexrazoxane may decrease the excretion rate of Procainamide which could result in a higher serum level. Procaine Dexrazoxane may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level. Procarbazine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Procarbazine. Promethazine Dexrazoxane may decrease the excretion rate of Promethazine which could result in a higher serum level. Propantheline Dexrazoxane may decrease the excretion rate of Propantheline which could result in a higher serum level. Propiverine Dexrazoxane may decrease the excretion rate of Propiverine which could result in a higher serum level. Propranolol Dexrazoxane may decrease the excretion rate of Propranolol which could result in a higher serum level. Propylthiouracil The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Propylthiouracil. Protein C The risk or severity of bleeding can be increased when Protein C is combined with Dexrazoxane. Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Dexrazoxane. Prucalopride Dexrazoxane may decrease the excretion rate of Prucalopride which could result in a higher serum level. Pyrantel Dexrazoxane may decrease the excretion rate of Pyrantel which could result in a higher serum level. Pyrazinamide Pyrazinamide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Pyridoxine Pyridoxine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Pyrithione Dexrazoxane may decrease the excretion rate of Pyrithione which could result in a higher serum level. Quetiapine Dexrazoxane may decrease the excretion rate of Quetiapine which could result in a higher serum level. Quinethazone Quinethazone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Quinidine Dexrazoxane may decrease the excretion rate of Quinidine which could result in a higher serum level. Rabeprazole Dexrazoxane may decrease the excretion rate of Rabeprazole which could result in a higher serum level. Rabies immune The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Dexrazoxane. Rabies antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dexrazoxane. Rabies antigen, B The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Dexrazoxane. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Dexrazoxane. Ramelteon Dexrazoxane may decrease the excretion rate of Ramelteon which could result in a higher serum level. Ranitidine Dexrazoxane may decrease the excretion rate of Ranitidine which could result in a higher serum level. Ranolazine Ranolazine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Rasagiline Dexrazoxane may decrease the excretion rate of Rasagiline which could result in a higher serum level. Ravulizumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ravulizumab. Reserpine Reserpine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Resorcinol Dexrazoxane may decrease the excretion rate of Resorcinol which could result in a higher serum level. Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Dexrazoxane. Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Dexrazoxane. Ribavirin Dexrazoxane may decrease the excretion rate of Ribavirin which could result in a higher serum level. Ribostamycin Dexrazoxane may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Rilonacept The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Rilonacept. Risankizumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Risankizumab. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Dexrazoxane. Rivaroxaban Dexrazoxane may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. Rizatriptan Dexrazoxane may decrease the excretion rate of Rizatriptan which could result in a higher serum level. Rofecoxib Rofecoxib may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Roflumilast Roflumilast may increase the immunosuppressive activities of Dexrazoxane. Ropeginterferon The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ropeginterferon alfa-2b. Ropivacaine Ropivacaine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Rosiglitazone Dexrazoxane may decrease the excretion rate of Rosiglitazone which could result in a higher serum level. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Dexrazoxane. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Dexrazoxane. Ruxolitinib The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ruxolitinib. Sacubitril Dexrazoxane may decrease the excretion rate of Sacubitril which could result in a higher serum level. Salbutamol Dexrazoxane may decrease the excretion rate of Salbutamol which could result in a higher serum level. Salicylamide Salicylamide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Salicylic acid Salicylic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Salmon calcitonin Salmon calcitonin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Salsalate Salsalate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Sarilumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sarilumab. Satralizumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Satralizumab. Saxagliptin Dexrazoxane may decrease the excretion rate of Saxagliptin which could result in a higher serum level. Secobarbital Dexrazoxane may decrease the excretion rate of Secobarbital which could result in a higher serum level. Secukinumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Secukinumab. Selenious acid Dexrazoxane may decrease the excretion rate of Selenious acid which could result in a higher serum level. Selenium Dexrazoxane may decrease the excretion rate of Selenium which could result in a higher serum level. Sibutramine Dexrazoxane may decrease the excretion rate of Sibutramine which could result in a higher serum level. Siltuximab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Siltuximab. Siponimod The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dexrazoxane. Sirolimus The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sirolimus. Sitagliptin Dexrazoxane may decrease the excretion rate of Sitagliptin which could result in a higher serum level. SVaccine, Live The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Dexrazoxane. Sodium acetate Dexrazoxane may decrease the excretion rate of Sodium acetate which could result in a higher serum level. Sodium Dexrazoxane may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level. Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Dexrazoxane. Sodium fluoride Dexrazoxane may decrease the excretion rate of Sodium fluoride which could result in a higher serum level. Sodium sulfate Dexrazoxane may decrease the excretion rate of Sodium sulfate which could result in a higher serum level. Sofosbuvir Dexrazoxane may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. Solriamfetol Dexrazoxane may decrease the excretion rate of Solriamfetol which could result in a higher serum level. Sorafenib The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sorafenib. Sorbitol Dexrazoxane may decrease the excretion rate of Sorbitol which could result in a higher serum level. Spesolimab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Spesolimab. Spironolactone Spironolactone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Stiripentol Dexrazoxane may decrease the excretion rate of Stiripentol which could result in a higher serum level. Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Dexrazoxane. Streptomycin Dexrazoxane may decrease the excretion rate of Streptomycin which could result in a higher serum level. Streptozocin The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Streptozocin. Strontium chloride Dexrazoxane may decrease the excretion rate of Strontium chloride which could result in a higher serum level. Sucralfate Sucralfate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Sulbactam Dexrazoxane may decrease the excretion rate of Sulbactam which could result in a higher serum level. Sulfadiazine Sulfadiazine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Dexrazoxane. Sulfasalazine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sulfasalazine. Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Dexrazoxane. Sulindac Sulindac may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Dexrazoxane. Sumatriptan Dexrazoxane may decrease the excretion rate of Sumatriptan which could result in a higher serum level. Sunitinib The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sunitinib. S Estrogens, A Dexrazoxane may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level. S Estrogens, B Dexrazoxane may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level. Tacrolimus Tacrolimus may increase the immunosuppressive activities of Dexrazoxane. Tadalafil Dexrazoxane may decrease the excretion rate of Tadalafil which could result in a higher serum level. Tamsulosin Dexrazoxane may decrease the excretion rate of Tamsulosin which could result in a higher serum level. Teduglutide Dexrazoxane may decrease the excretion rate of Teduglutide which could result in a higher serum level. Tegafur Dexrazoxane may decrease the excretion rate of Tegafur which could result in a higher serum level. Telavancin Dexrazoxane may decrease the excretion rate of Telavancin which could result in a higher serum level. Temazepam Temazepam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Temozolomide The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Temozolomide. Temsirolimus The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Temsirolimus. Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Dexrazoxane. Teniposide The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Teniposide. Tenofovir alafenamide The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dexrazoxane. Tenofovir disoproxil Tenofovir disoproxil may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Tenoxicam Tenoxicam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Teprotumumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Teprotumumab. Terbutaline Dexrazoxane may decrease the excretion rate of Terbutaline which could result in a higher serum level. Teriflunomide The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Teriflunomide. Testolactone Dexrazoxane may decrease the excretion rate of Testolactone which could result in a higher serum level. Testosterone Dexrazoxane may decrease the excretion rate of Testosterone which could result in a higher serum level. Testosterone Dexrazoxane may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. Testosterone enan Dexrazoxane may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. Testosterone propi Dexrazoxane may decrease the excretion rate of Testosterone propionate which could result in a higher serum level. Testosterone Dexrazoxane may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level. Tetracycline Dexrazoxane may decrease the excretion rate of Tetracycline which could result in a higher serum level. Tetradecyl Dexrazoxane may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level. Thalidomide The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Thalidomide. Thiabendazole Dexrazoxane may decrease the excretion rate of Thiabendazole which could result in a higher serum level. Thiethylperazine Thiethylperazine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Thiotepa The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Thiotepa. Tiaprofenic acid Tiaprofenic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Dexrazoxane. borne encephalitis The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Dexrazoxane. Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Dexrazoxane. Tiludronic acid Dexrazoxane may decrease the excretion rate of Tiludronic acid which could result in a higher serum level. Timolol Timolol may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Tinidazole Dexrazoxane may decrease the excretion rate of Tinidazole which could result in a higher serum level. Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Dexrazoxane. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Dexrazoxane. Tiopronin Dexrazoxane may decrease the excretion rate of Tiopronin which could result in a higher serum level. Tiotropium Dexrazoxane may decrease the excretion rate of Tiotropium which could result in a higher serum level. Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Dexrazoxane. Tixocortol The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Tixocortol. Tobramycin Dexrazoxane may decrease the excretion rate of Tobramycin which could result in a higher serum level. Tocilizumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Tocilizumab. Tocopherol Dexrazoxane may decrease the excretion rate of Tocopherol which could result in a higher serum level. Tofacitinib Dexrazoxane may increase the immunosuppressive activities of Tofacitinib. Tolazamide Dexrazoxane may decrease the excretion rate of Tolazamide which could result in a higher serum level. Tolbutamide Dexrazoxane may decrease the excretion rate of Tolbutamide which could result in a higher serum level. Tolcapone Tolcapone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Tolfenamic acid Tolfenamic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Tolmetin Tolmetin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Tolterodine Dexrazoxane may decrease the excretion rate of Tolterodine which could result in a higher serum level. Tolvaptan Tolvaptan may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Topiramate Topiramate may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Topotecan The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Topotecan. Torasemide Torasemide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Dexrazoxane. Trabectedin The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Trabectedin. Tramadol Tramadol may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Trametinib Dexrazoxane may decrease the excretion rate of Trametinib which could result in a higher serum level. Trastuzumab Trastuzumab may increase the neutropenic activities of Dexrazoxane. Trastuzumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Trastuzumab emtansine. Tretinoin The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Tretinoin. Triamcinolone The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Triamcinolone. Triamterene Triamterene may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Triazolam Dexrazoxane may decrease the excretion rate of Triazolam which could result in a higher serum level. Trichlormethiazide Trichlormethiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy. Triethylenetetramine Dexrazoxane may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level. Trifluridine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Trifluridine. Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Dexrazoxane. Trilostane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Trilostane. Trimebutine Dexrazoxane may decrease the excretion rate of Trimebutine which could result in a higher serum level. Trimethoprim Dexrazoxane may decrease the excretion rate of Trimethoprim which could result in a higher serum level. Trimetrexate Dexrazoxane may decrease the excretion rate of Trimetrexate which could result in a higher serum level. Tropisetron Dexrazoxane may decrease the excretion rate of Tropisetron which could result in a higher serum level. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Dexrazoxane. Typhoid Vaccine The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Dexrazoxane. Typhoid Vi The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Dexrazoxane. Upadacitinib The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Upadacitinib. Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Dexrazoxane. Vaborbactam Dexrazoxane may decrease the excretion rate of Vaborbactam which could result in a higher serum level. Valaciclovir Valaciclovir may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Valentine Dexrazoxane may decrease the excretion rate of Valbenazine which could result in a higher serum level. Valdecoxib Valdecoxib may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Valganciclovir Dexrazoxane may decrease the excretion rate of Valganciclovir which could result in a higher serum level. Vancomycin Dexrazoxane may decrease the excretion rate of Vancomycin which could result in a higher serum level. Varenicline Dexrazoxane may decrease the excretion rate of Varenicline which could result in a higher serum level. Varicella vaccine The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Dexrazoxane. Varicella zoster The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Dexrazoxane. Vedolizumab The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Vedolizumab. Venlafaxine Venlafaxine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. Verapamil Dexrazoxane may decrease the excretion rate of Verapamil which could result in a higher serum level. Vibrio cholerae The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Dexrazoxane. Vilanterol The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Vilanterol. Viloxazine Dexrazoxane may decrease the excretion rate of Viloxazine which could result in a higher serum level. Vinblastine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Vinblastine. Vincristine The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Vincristine. Pregnancy and Lactation FDA Pregnancy Risk Category: C  Pregnancy The manufacturer makes no recommendation regarding use during pregnancy. This drug can cause fetal harm; if this drug is used during pregnancy, or the patient becomes pregnant, apprise them of the potential hazard to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 3 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose. Lactation No information is available on the use of dexrazoxane during breastfeeding. The manufacturer recommends that women not breastfeed during treatment and for 2 weeks following the final dose of dexrazoxane. However, because dexrazoxane is used with doxorubicin, the abstinence period might be longer, depending on the doxorubicin dose. How should this medicine be used?

Dexrazoxane injection comes as a powder to be mixed with liquid and injected into a vein by a doctor or nurse in a hospital. When dexrazoxane injection is used to prevent heart damage caused by doxorubicin, it is given over 15 minutes just before each dose of doxorubicin. When dexrazoxane injection is used to prevent tissue damage after an anthracycline medication has leaked out of a vein, it is given over 1 to 2 hours once a day for 3…

Continue exploring

Explore this topic across the RX Medical Library

Open a focused A–Z pathway or continue with closely related indexed articles. These links are educational and do not replace personal medical care.

Search this topic
Diseases A–Z Drugs A–Z Lab Tests A–Z Cancer A–Z
Diseases A–Z

Foodborne Illness (also foodborne disease and colloquially referred to as food poisoning)[rx] is any illness resulting from the spoilage of contaminated food, pathogenic bacteria, viruses, or parasites that…

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)